Browse more cannabis research, findings, methods, and limitations.
A review argues CBD's antipsychotic effects and low side effect profile make it potentially ideal for early-phase psychosis, where minimizing adverse experiences is crucial.
A study of 515 men found cannabis-dependent individuals had distinct personality profiles and a different frequency of the DRD2 rs1799732 dopamine receptor gene variant.
A study of 44,007 adults aged 50+ found cannabis users had more ER visits but not more hospitalizations, with medical-only users driving the increased ER utilization.
In the ABCD Study, prenatal cannabis exposure was linked to more attention and behavior problems at ages 9-10, but no differences in cognitive performance or brain scans.
A pilot study of nanoparticle THC/CBD spray in 25 advanced cancer patients showed acceptable bioavailability, general safety, and preliminary pain relief, especially for bone metastases.
Among 383 IBD patients, cannabis users reported more pain, gas, and joint symptoms but did not have worse underlying disease, suggesting non-luminal factors drive their symptom burden.
Among substance use disorder patients, women with ADHD started cannabis use earlier and used longer than any other group, highlighting a gender-specific vulnerability.
Pharmaceutical CBD achieved 2.4x higher blood levels than artisanal CBD in children with epilepsy, with more side effects but a trend toward better seizure control.
Adolescent cannabis vapor exposure produced opposite brain changes in male and female mice: structural changes in females and functional connectivity disruption with cognitive deficits in males.
A review argues that combining CBD and THC may treat Alzheimer's more effectively than either alone, based on preclinical evidence of complementary neuroprotective mechanisms.
An Argentine ER study found alcohol increased road traffic injury risk nearly 7-fold, with combined alcohol-cannabis use showing similar risk, particularly among those under 30.
Cannabis withdrawal occurs in half of regular users, starting 24-48 hours after quitting and peaking within a week. No approved medications exist, but supportive counseling is first-line treatment.
Preclinical evidence for cannabinoids in Parkinson's and Alzheimer's is promising, but older adults are using them off-label despite almost no clinical trial data.
Hospital presentations for synthetic cannabinoid poisoning in the UK showed no change after the 2016 Psychoactive Substances Act banned their sale.
A survey of 284 frequent synthetic cannabinoid users found worse withdrawal, faster tolerance, and harder dose control compared to high-potency natural cannabis.
A survey of 342 terminally ill medical cannabis patients found very low hospice enrollment, suggesting cannabis may serve as an alternative rather than complement to end-of-life care.
A survey of 46 new mothers found most knew marijuana may be harmful while breastfeeding, but fewer than half knew THC enters breast milk, and only 30% received postnatal counseling.
A clinical guideline recommends atomoxetine for ADHD symptoms in patients with cannabis use disorder but finds it does not reduce cannabis use. Both atomoxetine and stimulants are considered safe in SUD patients.
A study of 2,945 young adults found racial/ethnic minorities experienced worse health, academic, and life satisfaction outcomes at the same levels of alcohol and cannabis use as White peers.
An international expert consensus concluded cannabis is a component cause of psychosis with dose-response and age-response relationships, but alone is neither necessary nor sufficient.
A survey of 258 menopausal women found 79% using cannabis for symptoms, most commonly sleep and anxiety, with perimenopausal women reporting worse symptoms and more anxiety-motivated use.
Medical cannabis patients showed improved brain white matter coherence on MRI over 6 months, contrasting with impairments in recreational users, with CBD exposure linked to improvements.
An open-label trial of full-spectrum CBD in 14 anxiety patients showed rapid response within one week, with improvements in anxiety, cognition, mood, and sleep over 4 weeks.
Among 539 university students, impulsiveness explained the link between problematic cannabis use and suicidal behavior, while childhood trauma amplified the cannabis-suicide attempt connection.
A study of 2,995 young adults found cannabis use predicted increasing anxiety over time, while anxious individuals actually reduced their cannabis use, challenging the self-medication hypothesis.
Cannabis users reported more schizotypy traits and subjective aberrant salience experiences, but showed normal salience processing on an objective lab task.
A systematic review of 11 studies found inconsistent evidence that cannabis or THC alleviates opioid withdrawal, with a potentially narrow therapeutic window.
Two long-term cannabis users had vitamin deficiencies and low cortisol that improved with supplements and psychotherapy.
Longitudinal research links prenatal cannabis exposure to lasting effects on behavior, memory, and substance use from childhood through adulthood.
Pregnant women with any cannabis use history were 6 to 11 times more likely to smoke cigarettes during pregnancy and postpartum.
A neuroscience-based school program for older teens reduced binge drinking, cannabis use, MDMA use, and nicotine use at 6 months.
Blocking the enzymes that break down natural endocannabinoids could offer a new approach to migraine pain without cannabis-related psychoactive effects.
Lab study showed CBD reduced inflammatory vesicles released from HIV-infected immune cells, potentially by lowering viral activity.
Nationwide data showed young adults with cannabis use disorder had higher rates of hypertensive crisis and worse cardiovascular outcomes during hospitalization.
Meta-analysis confirmed that acute exercise consistently increases endocannabinoid levels, potentially explaining mood and pain benefits of physical activity.
A high-CBD cannabis extract suppressed human T cell activity in the lab without killing cells, working mainly through CB2 and TRPV1 receptors.
CBD blocked THC-induced nausea in rats through 5-HT1A serotonin receptors and also reversed THC-induced stress hormone elevation.
Four rare cannabinoids (CBG, CBC, THCV, CBGA) each uniquely modulated the endocannabinoid system in human skin cells but shared common effects on receptor binding.
Review finds early evidence that CBD may safely improve symptoms of autism, intellectual disability, tics, and ADHD in children and adolescents.
NHANES data from over 21,000 adults linked past-30-day cannabis use to 54% higher odds of suicidal ideation and 53% higher odds of depression.
Large case-control study found no significant association between maternal cannabis use around pregnancy and autism spectrum disorder in children.
Social networks influenced how often young adults used cannabis, with stronger effects for recreational than medicinal users, but no link to problematic use.
Parrots naturally lack the CB2 cannabinoid receptor gene, making their brains more vulnerable to inflammation and demonstrating CB2's protective role.
A CB1 receptor enhancer fully blocked withdrawal-induced diarrhea and weight loss in opioid-dependent mice without cannabis-like side effects.
Research suggests CBD may work partly by changing DNA methylation patterns, offering a new explanation for its broad effects on anxiety, depression, and psychosis.
Qualitative study found price, quality, and social factors drive cannabis purchase decisions in Canada, while packaging and warnings have little influence.
Review of national survey data finds that cannabis legalization has not consistently increased adolescent use, and evidence-based education outperforms fear-based approaches.
Massachusetts cannabis industry data showed senior positions were 84% white and 82% male at 18 months, lagging behind overall workforce diversity.
Systematic review of 52 studies found some positive cannabis effects on palliative care symptoms, but all evidence was rated very low to low quality.
Large survey found about 1 in 5 residents reported secondhand cannabis smoke at home, with higher rates in multi-unit housing across both legal and illegal jurisdictions.